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IMPORTANCE The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has
been demonstrated to reduce the composite of myocardial infarction, stroke, or
cardiovascular death in patients with established atherosclerotic cardiovascular disease. To
our knowledge, long-term cost-effectiveness of this therapy has not been evaluated using
clinical trial efficacy data.
OBJECTIVE To evaluate the cost-effectiveness of evolocumab in patients with atherosclerotic
cardiovascular disease when added to standard background therapy.
DESIGN, SETTING, AND PARTICIPANTS AMarkov cohort state-transitionmodel was used,
integrating US population-specific demographics, risk factors, background therapy, and event
rates along with trial-based event risk reduction. Costs, including price of drug, utilities, and
transitional probabilities, were included from published sources.
EXPOSURES Addition of evolocumab to standard background therapy including statins.
MAIN OUTCOMES ANDMEASURES Cardiovascular events includingmyocardial infarction,
ischemic stroke and cardiovascular death, quality-adjusted life-year (QALY), incremental
cost-effectiveness ratio (ICER), and net value-based price.
RESULTS In the base case, using US clinical practice patients with atherosclerotic
cardiovascular disease with low-density lipoprotein cholesterol levels of at least 70mg/dL (to
convert to millimoles per liter, multiply by 0.0259) and an annual events rate of 6.4 per 100
patient-years, evolocumabwas associated with increased cost and improved QALY:
incremental cost, $105 398; incremental QALY, 0.39, with an ICER of $268637 per QALY
gained ($165 689with discounted price of $10 311 based onmean rebate of 29% for branded
pharmaceuticals). Sensitivity and scenario analyses demonstrated ICERs ranging from
$100 193 to $488642 per QALY, with ICER of $413 579 per QALY for trial patient
characteristics and event rate of 4.2 per 100 patient-years ($270 192 with discounted price of
$10 311) and $483 800 if no cardiovascular mortality reduction emerges. Evolocumab
treatment exceeded $150000 per QALY in most scenarios but would meet this threshold at
an annual net price of $9669 ($6780 for the trial participants) or with the discounted net
price of $10 311 in patients with low-density lipoprotein cholesterol levels of at least 80
mg/dL.
CONCLUSIONS AND RELEVANCE At its current list price of $14 523, the addition of evolocumab
to standard background therapy in patients with atherosclerotic cardiovascular disease
exceeds generally accepted cost-effectiveness thresholds. To achieve an ICER of $150000
per QALY, the annual net price would need to be substantially lower ($9669 for US clinical
practice and $6780 for trial participants), or a higher-risk population would need to be
treated.
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D espitemajoradvances in the treatmentofpatientswithatherosclerotic cardiovascular disease (ASCVD), sub-stantial riskof recurrent cardiac events, strokeevents,
and cardiovascular death remains aswell as high disease bur-
den affecting quality of life and costs.1-7 Lowering low-
density lipoprotein (LDL) cholesterol levelswith certain thera-
pies, including statins, reduces cardiovascular events.8,9 Yet,
manypatientswith establishedASCVDneed further LDL cho-
lesterol lowering and remain at substantial risk for cardiovas-
cular events despite optimal statin therapy.1,4,9 In the past 5
years, monoclonal antibodies that inhibit proprotein conver-
tasesubtilisin/kexintype9(PCSK9)havedemonstratedmarked
LDL cholesterol level lowering. Evolocumab, a fully human
monoclonal antibody against PCSK9, lowers LDL cholesterol
by approximately 60%.10-13 The evolocumab cardiovascular
outcomes trial, Further Cardiovascular Outcomes Research
With PCSK9 Inhibition in Subjects With Elevated Risk
(FOURIER),14 demonstrated that the addition of evolocumab
to standardbackground therapy, includingmoderate- tohigh-
intensity statin therapy, reduced incidence of cardiovascular
events in patients with established ASCVD.
Cost-effectiveness ofnew therapies is important ashealth
care costs rise, and accurate information about value and po-
tential tradeoffs among therapies is essential. Several analy-
ses have assessed the potential economic value of PCSK9 in-
hibitors in patient populations with varied risk levels,7,15-18
extrapolating cardiovascular event reduction rate ratios per
38.67mg/dLofLDLcholesterol reductionobserved in theCho-
lesterol Treatment Trialists Collaboration (CTTC) meta-
analyses of statin trials (to convert LDL cholesterol to milli-
moles per liter, multiply by 0.0259).8,19,20 To our knowledge,
the FOURIER results provide the first opportunity to assess
cost-effectiveness of evolocumab for the reduction of subse-
quentcardiovascularevents inanASCVDpopulationusingspe-
cific PCSK9 inhibition trial-based efficacy data.
In this study, aMarkov cohort state-transitionmodelwas
used to assess the cost-effectiveness of evolocumab when
added to standard background therapy in clinical practice pa-
tients with established ASCVD from a societal and US health
plan perspective to help better identify the patient popula-
tionsandvalue-basedpricewhere theuseofevolocumabtreat-
ment would provide value.
Methods
Model Structure
A Markov cohort state-transition model was used, consider-
ing the US societal perspective and assuming lifetime hori-
zon to capture the lifetime progression of ASCVD in adults. A
similar model to that used previously to estimate cost-
effectivenessandvalue-basedprice rangeofevolocumabusing
LDL cholesterol–lowering data from the statin trials and car-
diovascular event reduction fromCTTCmeta-analyses7,17was
used.Themodel (eFigure 1 in theSupplement)wasused topre-
dict subsequent cardiovascular events and cardiovascular- or
noncardiovascular-relatedmortality as a function of age, sex,
LDL cholesterol level, and cardiovascular event history. The
model transition-states were adapted to match those ana-
lyzed in FOURIER.14 The model comprises mutually exclu-
sive health states that include ASCVD, 2 acute event states
(myocardial infarction and ischemic stroke for a 1-year dura-
tion), and postevent health states and their combination that
are introduced to enable the model to account for event re-
currence. In addition, distinctions are made between cardio-
vascular andnoncardiovasculardeath.Revascularization is in-
cludedasaprocedureandnotasaseparatehealthstatebecause
it is assumed that it does not affect cardiovascular event risk
or quality of life.
Patient Population
A representative clinical practice-based population with es-
tablishedASCVDwasmodeled toembody theUSpatientpopu-
lation. Patients were selected from the US population–
weightedNationalHealth andNutritionExaminationSurveys
basedon individuals 18yearsorolder (meanage,66years)with
a recorded atherosclerotic cardiovascular condition and LDL
cholesterol level of at least 70mg/dL (mean, 104mg/dL)while
receiving statin therapy (Table 1). Written informed consent
was obtained from National Health and Nutrition Examina-
tion Surveyparticipants. The surveywas approvedby theNa-
tional Center for Health Statistics ethics review board.
The Truven MarketScan database, a large-scale database
of claims for commercially insuredpatients andpatientswith
Medicare Supplemental insurance,was used to estimate con-
temporary cardiovascular event rates for US patients with
ASCVD.15However, cardiovascular-relateddeathdatawerenot
complete inMarketScan. Cardiovascularmortality rateswere
estimated by combining multiple National Health and Nutri-
tion Examination Surveys death files (2004-2012) and Na-
tional Vital Statistics Report 2012.15 Rates were adjusted by
baseline LDL cholesterol levels and age and previous event
history.21 Ten-year and lifetime event rates for this popula-
tion are shown in eTable 1 in the Supplement. These rates re-
flect multiple events. For reference, the annual cardiovascu-
lar event rate (nonfatalmyocardial infarction, nonfatal stroke,
or cardiovascular death) was 6.4 per 100 patient-years in this
Key Points
Question What is the cost-effectiveness of the proprotein
convertase subtilisin/kexin type 9 inhibitor evolocumab in patients
with atherosclerotic cardiovascular disease?
Findings In this study, a Markov cohort state-transitionmodel
determined that adding evolocumab at current list price to
patients receiving standard background therapy was estimated to
cost $268637 per quality-adjusted life-year gained. Sensitivity and
scenario analyses demonstrated incremental cost-effectiveness
ratios ranging from $100 193 to $488642 per quality-adjusted
life-year.
Meaning To achieve a threshold of $150000 per quality-adjusted
life-year gained in patients with atherosclerotic cardiovascular
disease with low-density lipoprotein cholesterol levels of at least
70mg/dL and an annual event rate of 6.4 per 100 patient-years,
an annual net price of $9669 or a higher risk population would
need to be treated.
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US practice-based population, whereas in participants in the
FOURIER trial placeboplus standardbackground therapyarm,
the event rate (includingmultiple events)was 4.2 per 100pa-
tient-years (eTable 2 in the Supplement).14 Thenoncardiovas-
cular mortality rate was assumed to be that of the general US
population.22
Intervention Effects andModel Assumptions
Hazard ratios were based on landmark analysis of the indi-
vidual end points in FOURIER of nonfatal myocardial infarc-
tion, nonfatal ischemic stroke, and coronary revasculariza-
tion, with respective risk reductions of 21%, 26%, and 16% in
the first year and 36%, 25%, and 28% beyond year 1
(Table 2), as previously published.14 Cardiovascular event
rate ratios per 38.67 mg/dL of LDL cholesterol reduction
were derived from the hazard ratios and the LDL cholesterol
reduction reported in the trial (53.36 mg/dL) and then
applied in the model (Table 2). In FOURIER, cardiovascular
mortality reduction was not observed within the first 3 years
of follow-up. In the base case, risk reduction for cardiovas-
cular mortality was set at 0% for the first 5 years and then
estimated to proportionally match the cardiovascular mor-
tality event reduction in the CTTC meta-analysis8 for overall
or more vs less intensive statin therapy when appropriate
thereafter (risk reduction 9.5% per 38.67 mg/dL LDL choles-
terol reduction) (eTable 3 in the Supplement). The 5-year
delay before the emergence of cardiovascular mortality
reduction was selected in the base case to be consistent with
findings from contemporary greater-intensity LDL
cholesterol–lowering clinical outcome trials in which cardio-
vascular mortality reduction was not observed in the first 5
years.9,27,28 Consistent with the safety profile reported in
FOURIER, among patients receiving evolocumab, 2.1% were
assumed to develop mild injection site reactions over 2
years, resulting in a small quality-of-life decrement (Table 2).
Evolocumab therapy persistence rates over time were based
on those observed in FOURIER during the first 3 years of
follow-up and then kept steady. Within-trial persistence and
adherence effects on efficacy were already reflected in the
intention-to-treat hazard ratios reported in FOURIER during
the first 3 years and modeled as not further varying.
Costs and Utilities
Directmedicalcostsassociatedwithcardiovasculareventswere
obtained through US claims data23,24 and adjusted for infla-
tion to January 2017 using the Consumer Price Index.29 Indi-
rect cost estimates were obtained from the 2017 American
HeartAssociation/American StrokeAssociation report on car-
diovascular disease burden by applying reported ratios of di-
rect and indirect costs.25Noncardiovasculardeatheventswere
assumed to incur no costs and not vary by treatment alloca-
tion.Medicationcostofevolocumab in thebasecasewasbased
on the current wholesale acquisition cost for evolocumab,
$14 523 (list price). Additional analyseswereperformedbased
on theestimatedmeanannual net cost of $10311 (list pricemi-
nus anaverage rebate of 29% for brandedpharmaceuticals).30
The average of Red Book prices and the market share of ge-
neric simvastatin and atorvastatin were used for standard
therapy($68)andezetimibe($2780).31Additionalanalysesused
ezetimibepriced similarly to generic statin therapy ($68).Util-
Table 1. Baseline Characteristics of the Atherosclerotic Cardiovascular Disease Patient Population
in the FOURIER Trial and US Population FromNHANES
Characteristic FOURIER Trial
NHANES
LDL-C ≥70 mg/dL LDL-C ≥100 mg/dL
Age, mean (SD), y 63 (9) 66 (11) 64 (12)
Male sex, No. (%) 20 795 (75) 4 942 898 (61) 1 983 383 (59)
Race/ethnicity, No. (%)
White 23 426 (85) 6 395 502 (78) 2 483 397 (74)
Black or African American 699 (2) 659 089 (8) 378 565 (11)
Asian or other 3439 (12) 1 109 929 (14) 483 231 (14)
Cardiovascular risk factors, No. (%)
Hypertension 22 040 (80) 6 082 104 (74) 2 576 980 (77)
Diabetes mellitus 9333 (34) 2 102 232 (26) 913 607 (27)
Current cigarette use 7770 (28) 2 083 283 (26) 682 855 (20)
History of vascular disease, No. (%)a
Myocardial infarction 22 356 (71) 4 233 427 (52) 1 481 045 (44)
Ischemic stroke 5330 (17) 2 793 056 (34) 909 851 (27)
Other ASCVD 3640 (12) 1 138 038 (14) 954 297 (29)
Ezetimibe use, No. (%) 1393 (5) 571 044 (7) 178 285 (5)
Lipid parameters at parent study baseline
LDL-C, mean (SD), mg/dL 97 (28) 104 (28) 130 (27)
LDL-C 70-99 mg/dL, No. (%) 15 586 (57) 4 819 328 (59) 0
LDL-C ≥100 mg/dL, No. (%) 9943 (36) 3 345 193 (41) 3 345 193 (100)
HDL-C, mean (SD), mg/dL 46 (13) 50 (12) 48 (11)
Triglycerides, mean (SD), mg/dL 149 (70) 138 (74) 164 (85)
Abbreviations: ASCVD,
atherosclerotic cardiovascular
disease; FOURIER, Further
Cardiovascular Outcomes Research
With PCSK9 Inhibition in Subjects
With Elevated Risk;
HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density
lipoprotein cholesterol;
NHANES, National Health and
Nutrition Examination Surveys.
SI conversion factor: To convert
cholesterol levels to millimoles per
liter, multiply by 0.0259; to convert
triglycerides to millimoles per liter,
multiply by 0.0113.
a Percentage split in the history of
vascular disease is calculated using
the total number of previous
events, rather than the total
number of study participants, as is
used for the other characteristics.
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Table 2. Key Inputs in theModel
Input Value (95% CI) Source
Event rate per 100
patient-years, clinical
practice population
Nonfatal myocardial
infarction
2.3 (2.2-2.4)
US Claims Data, NHANES, NVS15
Nonfatal ischemic stroke 2.1 (2.0-2.2)
Cardiovascular-related
death
2.0 (1.9-2.1)
Coronary
revascularizationa
3.3 (3.1-3.4)
Event rate per 100
patient-years, trial
population
Nonfatal myocardial
infarction
2.5 (2.2-2.7)
FOURIER14
Nonfatal ischemic stroke 0.9 (0.8-1.1)
Cardiovascular-related
death
0.8 (0.7-1.0)
Coronary
revascularizationa
3.9 (3.6-4.3)
Intervention effect, hazard
ratiob
Nonfatal myocardial
infarction, 1 y/beyond 1 y
0.79 (0.67-0.93)/0.64 (0.54-0.76)
FOURIER14
Nonfatal ischemic stroke,
1 y/beyond 1 y
0.74 (0.55-1.00)/0.75 (0.58-0.98)
Coronary
revascularization,a
1 y/beyond 1 y
0.84 (0.74-0.96)/0.72 (0.63-0.82)
Intervention effect, rate
ratio per 38.67 mg/dL LDL-C
reduction
Nonfatal myocardial
infarction, 1 y/beyond 1 y
0.84 (0.75-0.95)/0.72 (0.64-0.82)
FOURIER, CTTC (2010)8,14
Nonfatal ischemic stroke,
1 y/beyond 1 y
0.80 (0.65-1.00)/0.81 (0.67-0.99)
Coronary
revascularization,a
1 y/beyond 1 y
0.88 (0.80-0.97)/0.79 (0.72-0.87)
Cardiovascular-related
death, up to
y 5/beyond 5 y
NAc/0.90 (0.85-0.95)
Direct cost, $
Other ASCVD 8501 (7870-9132)
US Claims Data23,24
Nonfatal myocardial
infarction,
year 1/beyond 1 y
52 084 (50 659-53 510)/8501 (7870-9132)
Nonfatal ischemic stroke,
year 1/beyond 1 y
46 207 (44 063-48 351)/8816 (7573-10 058)
Cardiovascular-related
death
76 537 (75 405-77 669)
Coronary
revascularizationa
59 384 (58 463-60 306)
Indirect cost, $
Nonfatal myocardial
infarction
57 936 (56 351-59 522) AHA Cardiovascular Disease
Burden Report25
Nonfatal ischemic stroke 37 465 (35 727-39 204)
Utilityd
Established ASCVD 0.824 (0.800-0.848)
Time Tradeoff Study26
Nonfatal myocardial
infarction, 1 y/beyond 1 y
0.672 (0.625-0.719)/0.824 (0.800-0.848)
Nonfatal ischemic stroke,
1 y/beyond 1 y
0.327 (0.264-0.390)/0.524 (0.472-0.576)
Injection site reaction,
disutility
0.0003
Discontinuation, % 15 over 3 y FOURIER14
Abbreviations: AHA, American Heart
Association; ASCVD, atherosclerotic
cardiovascular disease;
CTTC, Cholesterol Treatment Trialists
Collaboration; FOURIER, Further
Cardiovascular Outcomes Research
With PCSK9 Inhibition in Subjects
With Elevated Risk; NHANES,
National Health and Nutrition
Examination Surveys; NVS, Novartis,
LDL-C, low-density lipoprotein
cholesterol.
a Coronary revascularization was
defined as percutaneous coronary
intervention or coronary artery
bypass graft.
bHazard ratios are converted to rate
ratios per 38.67mg/dL using: rate
ratio per 38.67mg/dL =
exp(LN[hazard ratio]/[53.36/
38.67]) or equivalently: rate ratio
per 38.67mg/dL = hazard
ratio^(1/[53.36/38.67]), where
53.36 is the LDL-C reduction in
mg/dL observed in FOURIER.
c No reduction in cardiovascular
mortality in first 5 years assumed in
the base case.
d In utilities, 0 represents death, and
1 represents perfect health.
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ity estimates for cardiovascular health states were based on
results of a time tradeoff study.26
Base-Case Cost-effectiveness Analysis
The lifetime cost and quality-adjusted life-years (QALY) ac-
crued under the 2 treatment options, evolocumab added to
standard background therapy (moderate- to high-intensity
statin with or without ezetimibe) vs standard background
therapy alone,were projected through simulation. The incre-
mental cost-effectiveness ratio (ICER)wascalculatedas the in-
crementalcostperQALYgained.Theanalysisconsideredacost-
effectiveness threshold of $150000 per QALY gained in the
base case, aligned with the American College of Cardiology/
American Heart Association statement on cost/value meth-
ods for intermediate vs low value,32 recommendations from
the World Health Organization,33 and contemporary
literature.34 The annual net value–based price to achieve an
ICER of $150000 per QALY gainedwas calculated. A range of
willingness-to-pay thresholds were also considered.34,35 Ad-
ditionalmodel outcomes included theprobabilisticmeanand
95%credible intervals for thenetvalue–basedprice.TheQALY
and costs were discounted at an annual rate of 3.0%, consis-
tentwith the SecondUSPanel onCost-effectiveness inHealth
and Medicine recommendation.35
Sensitivity and Scenario Analyses
Sensitivity analyses were conducted to reflect uncertainty in
model inputs and to assess robustness of model outcomes.
In the deterministic sensitivity analyses, model parameter
values (Table 2) were varied individually through plausible
ranges (eg, 95% confidence intervals). Probabilistic sensitiv-
ity analyses examined the combined effect of parameter
uncertainty on the model results. A sensitivity analysis was
performed using the FOURIER patient population character-
istics and cardiovascular event rates analyses. We also ana-
lyzed in the clinical practice population analyses where the
background cardiovascular event rates were 25% and 50%
higher or lower of those in US clinical practice. As a sensitiv-
ity analysis, a range of cardiovascular mortality effect sizes
were applied to assess the effect on overall results (eTable 3
in the Supplement). Additional sensitivity analyses included
extreme cases where all hazard ratios were increased or
decreased simultaneously by 1 SE.
A range of scenario analyses were considered including
modeling a 3-year, 7-year, or infinite delay of treatment
effect on cardiovascular mortality; modeling treatment
effect on myocardial infarction, stroke, and cardiovascular
mortality based on the corresponding key secondary end
point from FOURIER; and modeling cost-effectiveness con-
fined to patients with ASCVD with baseline LDL cholesterol
levels of at least 100 mg/dL (mean, 130 mg/dL). A scenario
analysis was performed where the risk ratios derived from
the FOURIER key secondary end point did not vary from
year 1 and subsequent years. In addition, scenario analyses
with ezetimibe priced similarly to generic statin therapy
($68), where all patients with ASCVD were treated with
ezetimibe and statin therapy and where only the US payer
perspective was considered (no indirect costs) were per-
formed. We also analyzed what LDL cholesterol treatment
initiation threshold for the population would yield an ICER
of $150000 per QALY gained at current list price and current
net drug price (value-based LDL-cholesterol treatment ini-
tiation threshold). Furthermore, we determined the annual
event rate thresholds where the current list price and net
price of evolocumab would yield an ICER of $150000.
ThemodelwasdevelopedusingMicrosoftExcel 2013, ver-
sion 14.0 (Microsoft). The Impact InventoryTemplate and the
Reporting Checklist for Cost-effectiveness Analyses from the
Second Panel on Cost-effectiveness inHealth andMedicine35
are in eTables 4 and 5 in the Supplement.
Results
In the base case using a US clinical practice patient popula-
tion, the LDL cholesterol level was at least 70 mg/dL (mean,
104mg/dL) and the cardiovascular event ratewas 6.4 per 100
patient-years with standard background therapy. In this base
case,mean lifetimecostswouldbe$234877perpatient treated
with standard therapy and $340275 per patient treated with
evolocumab added to standard background therapy, with in-
cremental costs of $105 398 (Table 3; eTable 6 in the Supple-
ment). The lifetimeQALYwas 7.23with standard background
therapyand7.62with evolocumab,with adifference inhealth
effects of 0.39 QALY. Compared with standard background
therapy alone, use of evolocumab at its current list price
($14 523) results in an ICER of $268 637 per QALY gained
(Table3). If, instead, anetpriceof evolocumabreflectinga29%
discount was used ($10 311), the ICER would be $165689 per
QALY. To achieve a value threshold of $150000 per QALY
gained, a value-based net price of $9669 annually would be
required (Table 3). The net value-based prices at ICERs of
$50000, $100000, $150000, $200000, and $250000 per
QALYwould be $5578, $7623, $9669, $11 715, and $13 760 per
year, respectively.For theFOURIER trial participants, the ICER
would be $413 579 per QALY, and the net value-based price
would be $6780 (Table 3). Net value-based prices at ICERs of
$50000, $100000, $150000, $200000, and $250000 per
QALYwouldbe$3843,$5312,$6780,$8249,and$9718peryear,
respectively.
Sensitivity Analyses
Whenwevaried thebackgroundcardiovascular event rates for
the US clinical practice population by 25% and 50%higher or
lower, the ICER ranged from $194551 to $488642 per QALY,
and the net value-based price ranged from $12 218 to $6164
(Table 4 andFigure). Testing the treatment benefit for cardio-
vascularmortality beginning after 5 years of follow-up across
risk reductions ranging from 14.0% to 6.4% per 38.67 mg/dL
LDLcholesterolyieldedanICERrangefrom$225575to$313 163
per QALY and a net value-based price range from $10773 to
$8872 (Table 4). Deterministic sensitivity analyses are pre-
sented in eFigure 2 in the Supplement. Probabilistic sensitiv-
ity analyses at list price revealed amean ICER of $275 124 per
QALY and a mean net value-based price of $9565, with 95%
of values between $6313 and $12418. The probabilistic mean
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and 95% credible intervals of the net value-based prices are
shown in eFigure 3 in the Supplement.
Scenario Analyses
We tested various assumptions of the treatment benefit
(Table 4). A 3-year time before cardiovascular mortality ben-
efits emerge yielded an ICER of $245066 and a value-based
net price of $10221 per year. A 7-year delay in the cardiovas-
cularmortality treatment benefit yielded an ICERof $293 720
perQALY, andanet value-basedprice of $9188per year. In the
caseofno lifetimecardiovascularmortality reduction, the ICER
was $483800 per QALY, and the net value-based price was
$7246. This reflects the improvements in the rate of subse-
quent events, health state utilities (the quality of the life-
years), andcardiovasculardiseaseeventsandprocedures costs
by reducingnonfatal events, even in the absenceof direct sur-
vival benefit. Additional scenarios are shown in Table 4. If all
patientswere receiving ezetimibe and statin therapy, then the
ICER was $271 313. When only the US payer perspective was
integrated into the model, then the ICER was $304 392 per
QALY, and thenet value-basedpricewas $8206.At current list
price, theLDLcholesterol treatment initiation threshold forpa-
tients with ASCVD that would yield an ICER of $150000 per
QALY was calculated to be at least 119 mg/dL (at this thresh-
old, mean LDL cholesterol level for the ASCVD population is
144 mg/dL) and at the discounted price at least 80 mg/dL (at
this threshold,meanLDLcholesterol level for theASCVDpopu-
lation is 110mg/dL).Theannualevent rate for theASCVDpopu-
lation thatwould yield an ICERof $150000perQALYwas cal-
culated to be 13.5 per 100patient-years at list price and 7.1 per
100 patient-years at the discounted price.
Discussion
In this study, amodel basedon the clinical risk reductiondem-
onstrated inFOURIERandextrapolatedover lifetimewasused
to investigate the economic value of evolocumab in aUS clini-
cal practice–based population of patients with established
ASCVD. This evaluationhas found that evolocumab at its cur-
rent list price of $14 523,when added to standard background
therapy, including statins, inpatientswith establishedASCVD
with a background event rate of 6.4 per 100patient-years had
an ICER of $268637. This ICER exceeds the threshold estab-
lished by the World Health Organization for cost-effective-
ness and the American College of Cardiology/AmericanHeart
Association threshold for intermediate vs low value.32,33 The
ICER would be substantially higher if cardiovascular mortal-
ity benefitswith evolocumabwere not to emerge or if the car-
diovascular event rateswere similar to those inFOURIER.Evo-
locumab therapy could meet the threshold of $150000 per
QALY with an annual value-based price of $9669 for a popu-
lation with an event rate of 6.4 per 100 patient-years. This
evaluation provides insights as to the economic implications
of evolocumab therapy if applied to eligible patients with
ASCVD in US clinical practice.
Sensitivity and scenario analyses resulted in ICERs that,
with few exceptions, exceeded the American College of Car-
diology/American Heart Association intermediate value and
WorldHealthOrganizationcost-effectiveness thresholds.How-
ever, a value-based net annual price of $9669 would yield an
ICER of $150 000 per QALY in an ASCVD clinical practice
population.32,33 The treatment effect on cardiovascular mor-
tality in thebasecase is supportedbydata frommendelian ran-
domization analyses demonstrating virtually identical lower
odds of coronary heart diseasemortality in patientswith life-
long geneticallymediated lower LDL cholesterol levels either
fromvariants in 3-hydroxy-3-methylglutaryl-coenzymeA re-
ductase or in PCSK9.36 In the scenario that no cardiovascular
mortality benefitwas to emerge, the ICERwould be $483800
per QALY gained, substantially exceeding current intermedi-
ate value and cost-effectiveness thresholds. The base case re-
flects thecharacteristicsandevent ratesofpatientswithASCVD
in US clinical practice. If the characteristics and event rates
Table 3. Total Costs, QALY, and ICER
Base Case and Sensitivity Analyses
Cost, $ QALY
ICER, $ VBP, $aTotal Incremental Total Incremental
Base case, full list price, US clinical practice
Standard therapy alone 234 877 NA 7.23 NA NA NA
Evolocumab added to standard therapy 340 275 105 398 7.62 0.39 268 637 9669
Discounted net price, US clinical practice
Standard therapy alone 234 877 NA 7.23 NA NA NA
Evolocumab added to standard therapy 299 884 65 007 7.62 0.39 165 689 9669
Full list price, FOURIER trial participants
Standard therapy alone 228 015 NA 9.59 NA NA NA
Evolocumab added to standard therapy 367 833 139 817 9.93 0.34 413 579 6780
Discounted net price, FOURIER trial participants
Standard therapy alone 228 015 NA 9.59 NA NA NA
Evolocumab added to standard therapy 319 358 91 343 9.93 0.34 270 192 6780
Abbreviations: FOURIER, Further Cardiovascular Outcomes ResearchWith
PCSK9 Inhibition in Subjects With Elevated Risk; ICER, incremental
cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-years;
VBP, value-based price.
a Value-based price is net annual price to achieve an incremental
cost-effectiveness ratio of $150000 per quality-adjusted life-years.
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Table 4. Sensitivity and Scenario Analyses
Scenario Base-Case Assumption Scenario Assumption
ICER, $
VBP, $aList Price
Discounted
Net Price
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
A reduction of 6.4% in CV
mortality per 38.67
mg/dL LDL-C reduction
313 163 191 539 8872
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
A reduction of 14.0% in
CV mortality per 38.67
mg/dL LDL-C reduction
225 575 140 688 10 773
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
3-y delay in CV mortality
benefit
245 066 151 983 10 221
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
7-y delay in CV mortality
benefit
293 720 180 258 9188
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
No CV mortality benefit 483 800 290 601 7246
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
Key secondary end point
in FOURIER
160 934 106 567 13 676
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
Individual end point for
nonfatal MI and nonfatal
IS with benefit the same
in all years
286 577 182 226 9010
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
All HRs varied 1 SE lower
simultaneously
193 260 114 202 12 218
Intervention
effect
Individual end point for
nonfatal MI, nonfatal IS, and RV
from FOURIER; benefit less in
first year and greater in second
year and beyond; 5-year delay
in CV mortality benefit
All HRs varied 1 SE higher
simultaneously
429 364 275 893 6856
Price of
ezetimibe, $
Net price, 2780 Net price, 68 268 441 165 493 9677
Ezetimibe use in
all patients
Ezetimibe use in 7% All patients treated with
statin and ezetimibe as
background therapy
271 313 168 365 9560
Annual event rates
from FOURIER
Annual event rate of 6.4 per
100 patient-years
Annual event rate of 4.2
per 100 patient-years
413 579 270 192 6780
Annual event rates
25% lower
US practice
Annual event rate of 6.4 per
100 patient-years
Annual event rate of 4.8
per 100 patient-years
341 974 216 762 8065
Annual event rates
25% higher
US practice
Annual event rate of 6.4 per
100 patient-years
Annual event rate of 8.0
per 100 patient-years
224 401 134 510 11 037
Annual event rates
50% lower
US practice
Annual event rate of 6.4 per
100 patient-years
Annual event rate of 3.2
per 100 patient-years
488 642 318 010 6164
(continued)
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are similar to those in FOURIER, treatment with evolocumab
would lead to an ICER of $413 579 and a value-based net an-
nual price of $6780.
Despite significantly higher medication costs, the incre-
mental reduction in cardiovascular events, corresponding re-
ductions in hospitalizations, and revascularizations resulting
from the addition of evolocumab therapy drives the ICER. In
patients with established ASCVD who, with other currently
available lipid-modifying therapies including maximally tol-
eratedstatins, requireadditionalLDLcholesterol lowering,add-
ing evolocumab could facilitate improved clinical outcomes
foraconsiderableproportionofpatients.15,16 Substantialpopu-
lation health improvements and further progress toward re-
duction in noncommunicable diseases could result.15 How-
ever, with an ICER of $268637 per QALYwith the current list
price, there are legitimate concerns regarding the appropri-
ate allocation of health care resources along with challenges
in coverage and access to this therapy, despite demonstration
of clinical event reduction in FOURIER. Adopting a net value-
based price of $9669 annually would be 1 potential strategy
that could affect the valueproposition andwillingness to pay.
Targeting a subset of patientswithASCVDwho are at particu-
larly high risk for events based on clinical factors, formal risk
scores, or use of a higher LDL cholesterol treatment initiation
threshold for the addition of evolocumab therapy would be
alternative approaches to improve value and limit
expenditures.16 At an LDL cholesterol treatment initiation
threshold of at least 100 mg/dL, evolocumab therapy would
be cost-effective with an ICER of $100 193 per QALY for a US
clinical practice ASCVD population, with an event rate of 6.4
per 100 patient-years, but only at a net price of $10 311.
This study provides, to our knowledge, the first cost-
effectiveness data on evolocumab integrating the results of
FOURIER. Prior cost-effectiveness analyses of PCSK9 inhibi-
tion have been published based on the projected benefits of
LDL cholesterol lowering on clinical events, with variable
findings.15-17 A prior analysis using a similar model from a US
payer perspective suggested therapy at list price was cost-
effective for patients with established ASCVD and LDL cho-
lesterol levels of 100 mg/dL or higher.17 In contrast, a study
Figure. Incremental Cost-effectiveness Ratios and Value-Based Pricing by Annual Cardiovascular Event Rates
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A, Incremental cost-effectiveness ratio (ICER) values for a range of annual
cardiovascular event rates per 100 patient-years using full list price ($14 523 per
year) and discounted net price ($10 311 per year) for evolocumab for the US
clinical practice population. Annual cardiovascular event rate per 100
patient-years integrates multiple events into the rates (patients may experience
more than 1 event). B, ICER values for a range of annual cardiovascular event
rates per 100 patient-years using full list price ($14 523 per year) and discounted
net price ($10 311 per year) for evolocumab for the FOURIER trial population. C,
Value-based prices (VBPs) at range of annual cardiovascular event rates per 100
patient-years for the US clinical practice population and for the FOURIER trial
participants.
Table 4. Sensitivity and Scenario Analyses (continued)
Scenario Base-Case Assumption Scenario Assumption
ICER, $
VBP, $aList Price
Discounted
Net Price
Annual event rates
50% higher
US practice
Annual event rate of 6.4 per
100 patient-years
Annual event rate of 9.6
per 100 patient-years
194 551 113 142 12 218
Perspective Societal Payer (exclude indirect
cost)
304 392 201 444 8206
LDL-C threshold,
mg/dL
LDL-C ≥70 LDL-C ≥100 (mean, 130) 172 194 100 193 13 225
Annual event rate
threshold
Annual event rate of 6.4 per
100 patient-years
Annual event rate to be
cost-effective at current
list price, 13.5 per 100
patient-years
150 000 80 210 14 523
Annual event rate
threshold
Annual event rate of 6.4 per
100 patient-years
Annual event rate to be
cost-effective at current
list price 7.1 per 100
patient-years
246 303 150 000 10 311
Abbreviations: CV, cardiovascular;
FOURIER, Further Cardiovascular
Outcomes ResearchWith PCSK9
Inhibition in Subjects With Elevated
Risk; HR, hazard ratio;
ICER, incremental cost-effectiveness
ratio; IS, ischemic stroke;
LDL-C, low-density lipoprotein
cholesterol; MI, myocardial infarction;
RV, coronary revascularization;
VBP, value-based price.
SI conversion factor: To convert
LDL-C tomillimoles per liter, multiply
by 0.0259.
a Value-based price is net annual price
to achieve an incremental
cost-effectiveness ratio of
$150000 per quality-adjusted
life-years.
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using theCoronaryHeartDiseasePolicymodel fromaUSpayer/
healthsystemperspectiveconcludedthatPCSK9inhibitionwas
not cost-effective.16 Several methodological differences may
account for the discrepancies in these priormodeling studies
and the Coronary Heart Disease Policymodelmay underesti-
mate event risk overall.37,38 The policy model did not con-
sider indirect costs.
Limitations
This study has several limitations. The results should be in-
terpretedwithin the context of the data inputs andmodeling
assumptionsused.Clinicaloutcomesdata fromFOURIERwere
limited to a median follow-up of 26 months, yet model pre-
dictions are basedon the assumption that clinical benefits ex-
tend beyond the period with direct follow-up. If the clinical
benefits differ from those modeled in this study, particularly
in regards to themagnitudeand timingof cardiovascularmor-
tality reductions, the cost-effectiveness findings could be af-
fected by overestimating or underestimating the cost-
effectiveness of evolocumab therapy. Cost-effectiveness
estimatescouldalsobealtered if significantadverseeventsma-
terializebeyond3 to4years of observation todate.39 If the lev-
els of persistencewith and adherence to evolocumab therapy
differ from those in FOURIER, costs and clinical effective-
ness may be affected. This economic evaluation included in-
direct costs to apply the US societal perspective, as is
preferred,32 but detailed data on indirect costs for each con-
ditional state are limited. This analysis is only applicable toUS
patients with established ASCVD and is not generalizable to
primary prevention patients, other populations at lower car-
diovascular event risk, or patients outside the United States.
Conclusions
At its current listpriceof$14523, theadditionofevolocumabto
standardbackground therapy inpatientswithASCVDprovides
a treatment option that exceeds generally accepted cost-
effectiveness thresholds. To achieve an ICER of $150000 per
QALYgained inaUSclinicalpracticeASCVDpopulationwithan
annualevent rateof6.4per 100patient-years, aprice reduction
with a net annual price of $9669 orwith an annual net price of
$10311 targeting treatment inpatientswithLDLcholesterol lev-
elsof80mg/dLorhigherwouldbeneeded.FortheFOURIERtrial
participants, with an annual event rate of 4.2 per 100 patient-
years,anetannualpriceof$6780wouldbenecessary.Thesefind-
ingshighlighttheneedforacomprehensivediseasemanagement
approachforASCVDthat includesvigorous lifestylechanges,as-
siduousadherence toall guideline-directed therapies, and judi-
cious use of new,more costly therapies.
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